BioSpace News Archive

Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced preliminary, top-line results of the Company’s placebo controlled Phase 2 stroke study (non-GCP) that was conducted in Beijing, China

Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common stock, including 750,000 shares of common stock sold pursuant to the underwriter’s full exercise of its option to purchase additional shares,

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology services to the worldwide biotechnology, biotherapeutics, and other industries, today announced a collaboration with SinuSys Corporation

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced the pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.

Challenge aimed at improving patient outcomes by identifying solutions to reduce time between diagnosis and treatment for lung cancer patients

Dr. Manon Cox will assume the role of CEO and Dr. Gary Grohmann the role of Chief Regulatory Officer, while retaining their positions on the Board of Directors, along with existing member Michael Bernard , JD, Chief Tax Officer for Vertex, Inc.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an update on the Phase III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program for the potential first-in-class investigational bifunctional immunotherapy bintrafusp alfa, in difficult-to-treat cancers, including biliary tract cancer (BTC) and cervical cancer.

Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel therapies for patient suffering from acute respiratory conditions, announced today that it has appointed Mark Coleman M.D. to its Board of Directors.

Aerobiotix today announced a strategic partnership with the Association for Professionals in Infection Control and Epidemiology ( APIC ), the largest association for infection prevention and control (IPC) professionals. Since 2018, Aerobiotix has been a Strategic Partner and has again signed on as a 2021 APIC Strategic Partner.